NASDAQ:SNGX
Soligenix, Inc Stock News
$0.405
+0 (+0%)
At Close: May 03, 2024
Soligenix Stock Plummets After It Announces Not To Pursue Rolling US Application Submission For HyBryte
08:39am, Monday, 10'th May 2021
Soligenix Inc (NASDAQ: SNGX) shares dropped during premarket after the company said it would not pursue a rolling marketing application submission for HyBryte (SGX301). Instead, it plans to submit
HyBryte™ Awarded Innovation Passport in the United Kingdom
07:30am, Monday, 10'th May 2021
PRINCETON, N.J., May 10, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr
Broad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting
07:30am, Tuesday, 04'th May 2021
PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr
Soligenix Presents at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research
07:30am, Wednesday, 28'th Apr 2021
PRINCETON, N.J., April 28, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
HyBryte™ Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting
07:00am, Monday, 26'th Apr 2021
PRINCETON, N.J., April 26, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Announces Presentations at Prominent Scientific Conferences
07:00am, Tuesday, 13'th Apr 2021
PRINCETON, N.J., April 13, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
07:00am, Wednesday, 07'th Apr 2021
PRINCETON, N.J., April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results
07:00am, Tuesday, 30'th Mar 2021
PRINCETON, N.J., March 30, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
SNGX Stock Price Increases Over 10% Pre-Market: Why It Happened
07:45am, Thursday, 04'th Mar 2021
The stock price of Soligenix, Inc. (NASDAQ: SNGX) has increased by over 10% pre-market. This is why it happened.
Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track
08:30am, Tuesday, 23'rd Feb 2021
New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ:
Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301
08:30am, Tuesday, 09'th Feb 2021
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercializati
Soligenix Poised to Announce US Commercialization Plans of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
08:30am, Monday, 25'th Jan 2021
New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatments for
Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
07:00am, Tuesday, 19'th Jan 2021
PRINCETON, N.J., Jan. 19, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
07:00am, Monday, 28'th Dec 2020
PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
